Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00600990 · ClinicalTrials.gov registry record · Phase 2
Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 624
- Enrollment target
NCT00600990 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 624 participants.
The verdict
NCT00600990, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 624 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of this medication in preventing nausea and vomiting in female patients at risk for post-operative nausea and vomiting (PONV).
Interventions
- DRUG GW597599
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 624 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00600990
The ClinicalTrials.gov registry entry for NCT00600990 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 624 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GW597599 is the first listed.
NCT00600990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00600990 about?
NCT00600990 is a clinical study titled "Study Of An NK-1 Anti-Emetic Medication For The Prevention Of Post-Operative Nausea And Vomiting In Female Patients". The purpose of this study is to determine the effectiveness of this medication in preventing nausea and vomiting in female patients at risk for post-operative nausea and vomiting (PONV).
What is the current status of trial NCT00600990?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 624 participants. The study started on 2004-12. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00600990?
The interventions under investigation include: GW597599 (DRUG).
Who is sponsoring clinical trial NCT00600990?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.